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Blood vesselThe growth and function of tissues are critically dependent on their vascularization. Adipose tissue is capable
of expanding many-fold during adulthood, therefore requiring the formation of new vasculature to supply
growing and proliferating adipocytes. The expansion of the vasculature in adipose tissue occurs through
angiogenesis, where new blood vessels develop from those pre-existing within the tissue. Inappropriate an-
giogenesis may underlie adipose tissue dysfunction in obesity, which in turn increases type-2 diabetes risk.
In addition, genetic and developmental factors involved in vascular patterning may deﬁne the size and ex-
pandability of diverse adipose tissue depots, which are also associated with type-2 diabetes risk. Moreover,
the adipose tissue vasculature appears to be the niche for pre-adipocyte precursors, and factors that affect
angiogenesis may directly impact the generation of new adipocytes. Here we review recent advances on the
basic mechanisms of angiogenesis, and on the role of angiogenesis in adipose tissue development and obesity. A
substantial amount of data points to a deﬁcit in adipose tissue angiogenesis as a contributing factor to insulin
resistance and metabolic disease in obesity. These emerging ﬁndings support the concept of the adipose tissue
vasculature as a source of new targets for metabolic disease therapies. This article is part of a Special Issue entitled:
Modulation of Adipose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The growth and function of all tissues and organs are critically de-
pendent on their appropriate vascularization. Blood ﬂow is important
for providing the correct oxygen tension in individual tissues, for the
delivery and removal of nutrients andwaste products, and for the transit
of cells involved in tissue immune surveillance. In addition to being crit-
ical for the health of individual tissues, blood ﬂowdelivers hormones and
growth factors that insure the inter-tissue and inter-organ communica-
tion necessary for whole body homeostasis. Thus, the growth of any
organ or tissue must be accompanied by parallel growth of its vascular
network.Most of the growthof organs and tissues occurs duringdevelop-
ment, and their ﬁnal size remains relatively constant through adulthood.
In contrast, adipose tissue is unique in that it can expand many-fold, to
comprise more than 40% of total body composition in obese individuals,
deﬁned as a bodymass index of 30 or higher. The ability of adipose tissue
to expandhas clear evolutionary advantages, enabling survival in times of
nutrient scarcity; however, concomitant with adipose tissue expansion
are metabolic alterations that enhance risk of metabolic disease. The
cellular and molecular mechanisms by which adipose tissue growth is
coordinated with the expansion of its capillary network are unknown.ion of Adipose Tissue in Health
ine, University of Massachusetts
66898.
rvera).
rights reserved.As these mechanisms may underlie the basis for adipose tissue dysfunc-
tion in metabolic disease, they comprise a fertile and exciting area of
research.
While the close association between weight gain and heightened
risk of type 2 diabetes (T2DM) is well established, not all individuals
with obesity become diabetic, and certain individuals become diabetic
after very minor weight gain [1]. This paradox is explained by the
large individual variation in the size and expandability of different adi-
pose tissue depots in humans, as expansion of some depots is associated
with increase risk, while expansion of others is associated with de-
creased risk [2]. Strikingly, each standard deviation (SD) increase in
subcutaneous adipose tissue mass decreases the odds of insulin resis-
tance by 48%. In contrast, each SD increase in visceral adipose tissue
mass increases the odds of insulin resistance by 80% [3]. The protective
effect of expandable subcutaneous fat depots duringweight gain is like-
ly to bedue to their capacity to properly store excess calories in the form
of triglycerides, thus preventing ectopic lipid deposition into muscle,
liver and visceral fat depots. Such ectopic deposition and inappropriate
lipid metabolism are thought to cause insulin resistance and result in a
greatly increased risk of T2DM [4,5]. Thus, understanding the speciﬁc
mechanisms by which the subcutaneous adipose tissue expands is of
particular interest, as these could provide new approaches for therapeu-
tic intervention in metabolic disease. Several lines of evidence indicate
that adipose tissue growth can be limited by its vascular supply [6–8],
raising the possibility that the angiogenic potential of speciﬁc depots
might be critical in limiting their maximal expandability. Testing this
hypothesis will require a deep understanding of the basic mechanisms
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factors that operate in different adipose tissue depots.
2. Basic molecular and cellular mechanisms of angiogenesis
The de-novo formation of blood vessels during the development of
the embryo occurs through the process of vasculogenesis, in which
mesoderm-derived precursors, called angioblasts, organize into the
ﬁrst primitive blood vessels. All further vessel growth during organ
and tissue development, as well as during tissue repair in adult organ-
ism, takes place through the process of angiogenesis, in which new
vessels sprout from pre-existing vasculature. It is likely therefore that
the vascularization of adipose tissue depots in adults proceeds through
angiogenic expansion of the existing vasculature, as has been shown to
occur during the formation of fat pads from implanted cells [9]. The last
few years have brought great insight into the basic molecular and
cellular mechanisms of angiogenesis [10–14], setting the stage for
the identiﬁcation of factors that regulate this process to fulﬁll tissue
and developmental stage speciﬁc functions. Key insights into the cellular
andmolecular bases for angiogenesis, derived from experimentalmodels
such as the developing zebraﬁsh embryo and the mouse retina, are very
brieﬂy summarized below.
The cardinal features of angiogenesis comprise the proliferation of
endothelial cells, their directed migration through the extracellular
matrix, the establishment of intercellular junctions, the formation of
a lumen, the organization of perivascular supporting cells, the anasto-
mosis with existing vessels, and the establishment of circulation. The
cardinal initiating event is the stimulation of endothelial cell prolifer-
ation, which is mediated by the VEGF family of growth factors. These
growth factors and their receptors have been established as master
regulators of endothelial cell growth. In particular, VEGF-A, acting
through the VEGFR2 (VEGF receptor 2, also known as KDR in humans
or Flk1 in mice) represents the most potent mitogenic and chemo
attractant signal for endothelial cells. In response to VEGF-A gradients,
endothelial cells divide, and acquire a speciﬁc phenotype (tip cell phe-
notype) characterized by the formation of branches and numerous
ﬁlopodia, which extend towards the direction in which the endothelial
cell migrates. The action of VEGFs and their receptors are critically
controlled by the Notch signaling pathway, which modulates the re-
sponsiveness of endothelial cells to VEGF, and their subsequent special-
ization. Thus, tip cells are characterized by high levels of expression of
Delta-like 4 (Dll4), which is a ligand for Notch. The stimulation of
Notch signaling by Dll4 in the tip cell suppresses VEGF signaling in ad-
jacent cell, resulting in the acquisition of a stalk-cell phenotype. The
continuous dynamic interaction between VEGF, Notch and Dll4 results
in the development of angiogenic sprouts. Newly formed sprouts are
then stabilized by interactions with smooth muscle cells and pericytes,
and become lumenized, through processes that appear to involve junc-
tional trans-membrane proteins such as VE-cadherin, as well as matrix
proteins which are broken down and reorganized dynamically during
vessel growth [14]. Newly formed sprouts anastomose with existing
vessels, thus extending tissue microcirculation.
While the basic steps of angiogenesis outlined above are expected
to operate, it is likely that the vascular network of each organ and tissue
will be established through key tissue-speciﬁcmechanisms. A prominent
example is the regulation of angiogenesis in the central nervous system,
where speciﬁc G-protein coupled receptors are uniquely expressed
and play dominant roles in angiogenic vascularization of the developing
brain [15,16].Whatmechanisms operate in adipose tissue, and how they
modulate the basic steps of angiogenesis described above, are outstand-
ing questions in adipose tissue biology.
3. Adipose tissue angiogenesis; what are the triggers?
One of the guiding questions for understanding angiogenic growth
in adipose tissue is whether themechanisms involved during embryonicand early postnatal development are similar to those involved in re-
sponse to excess calorie consumption in adults. In both cases, two
broad possibilities can be considered: First, angiogenic expansion may
be triggered in response to signals emanating from proliferating and en-
larging adipocytes. The second possibility is that angiogenic growth is
triggered by developmental and/or metabolic signals, and parallels or
precedes adipocyte proliferation and enlargement (Fig. 1). These two
possibilities are not mutually exclusive, and in all likelihood tissue ex-
pansion involves both local cues arising from expanding adipocytes, as
well as distant cues reﬂecting the developmental and metabolic states
of the whole organism.
The ﬁrst option, in which vascular growth ensues secondarily to
parenchymal growth is the canonical model for oncogenic vasculari-
zation [17–19]. In this model, the rapid growth of tumor cells and
the formation of a tumor mass elicit regions of hypoxia. Hypoxia is
sensed through multiple mechanisms, prominent amongst which is
the inactivation of oxygen-dependent prolyl-hydroxylases. Inactivation
of these enzymes results in the protection of HIF-1α from proteolytic
degradation, allowing its dimerization with constitutively expressed
HIF-1β to form the functional transcription factorHIF1. This transcription
factor potently activates a program of hypoxia adaptation, which in-
cludes decreased transcription and translation and increased VEGF-A
expression. The angiogenic expansion of the vasculature in response to
VEGF-A enhances blood ﬂow and relieves hypoxia, allowing further
tumor growth. This model, in which tumor growth is absolutely depen-
dent on stimulation of angiogenesis, forms the basis for the development
and use of anti-angiogenic therapies in cancer [11].4. Role of hypoxia in adipose tissue angiogenesis
Themost relevant evidence consistentwith a possible role for hypoxia
in adipose tissue angiogenesis are the ﬁndings that adipose tissue in ro-
dents becomes hypoxic in response to obesity that is rapidly induced
by high fat diet (HFD). This ﬁnding has been documented repeatedly,
using both chemical indicators of hypoxia, as well as direct monitoring
of tissue oxygen tension using microelectrodes [20–22]. Using directly
placed microelectrodes, adipose tissue in obese humans has been found
to be hypoxic [23]. Other ﬁndings consistent with a role for hypoxia are
that the expression and secretion of pro-angiogenic factors by cultured
adipocytes are strongly stimulated under low oxygen culture condi-
tions [24]. These results suggest that, in a manner analogous to that oc-
curring during tumor growth, adipose tissue hypoxia might be a driver
for angiogenesis. However, the reported levels of hypoxia in human
adipose tissue are relatively small, and one study actually ﬁnds increased
oxygen tension in adipose tissue of obese subjects [25]. Moreover, it has
been previously noted that expansion of adipose tissue in response to
HFD is not accompanied by a corresponding increased blood ﬂow [26].
Collectively, these results suggest that the response to hypoxia in adipose
tissue may be insufﬁcient to elicit sufﬁcient compensatory angiogenic
expansion.
A powerful, direct approach to deﬁning the role of hypoxia in adipose
tissue growth has been the tissue-speciﬁc overexpression and ablation of
both HIF-1α and HIF-1β. Overexpression of a constitutively active form
of HIF-1α in adipose tissue failed to induce a pro-angiogenic response;
rather, it resulted in a ﬁbrotic response and an increase in local inﬂam-
mation [27]. Conversely, ablation of HIF-1α or HIF-1β (ARNT) in adipose
tissue reduced fat formation, and protected from HFD-induced obesity
and insulin resistance [28,29]. Furthermore, anti-sense mediated deple-
tion of HIF-1α in obese mice resulted in amelioration of HFD-induced
insulin resistance [30], as did pharmaceutical inhibition of HIF-1α, as
well as inducible expression of a dominant negative form [31]. Overall,
these results are consistent with a model where adipose tissue hypoxia
induces HIF-1α, which induces a ﬁbrotic and inﬂammatory response
rather than a compensatory pro-angiogenic response. Nevertheless,
HIF-1α may be relevant for the growth and maintenance of brown
Fig. 1. Two possible models for the stimulation of angiogenesis during adipose tissue growth. A. Increased calorie consumption results in adipocyte hypertrophy and hyperplasia,
generating areas of tissue hypoxia. Hypoxia, and/or other factors released from the tissue stimulate angiogenesis. Angiogenesis results in mitigation of hypoxia and appropriate
tissue architecture and function. B. Increased calorie consumption results in systemic changes in trophic factors such as insulin, which directly stimulate angiogenesis within
adipose tissue. Increased angiogenesis facilitates lipid storage in adipocytes and adipocyte hyperplasia. The simultaneous expansion of adipocytes and vasculature prevents devel-
opment of hypoxia and metabolic stress.
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impairs thermogenesis and energy expenditure [32].5. Role of VEGF in adipose tissue angiogenesis
In tumor angiogenesis, hypoxia-induced HIF1 stabilization activates
VEGF transcription and secretion, which in turn stimulates angiogene-
sis. The induction of ﬁbrosis and inﬂammation by HIF-1α in adipose tis-
sue suggests that the stimulation of VEGF productionmay be controlled
by different mechanisms, which are insufﬁciently activated during the
rapid expansion induced by high-fat diets or hyperphagia. Consistent
with this notion, transgenic overexpression of VEGF in adipose tissue
results in increased vascularization, decreased inﬂammation, and ame-
lioration of HFD-induced insulin resistance [33–35]. More strikingly,
induced expression of VEGF-A in adipose tissue of animals previously
rendered obese and insulin resistant reversed the establishedmetabolic
defects [33]. Expression of VEGF-A also caused the generation of adipo-
cytes expressing UCP1, which are more similar to brown adipose tissue
and have a highermetabolic rate, and result in lowerweight gain under
conditions of HFD [36].
Conversely, ablation of VEGF in adipose tissue resulted in hypo-
perfused adipose tissue, which displayed higher levels of inﬂammato-
ry markers even under normal chow diet. In response to HFD feeding
adipose tissue from VEGF-ablated animals developed much greater
inﬂammation compared to controls [33]. This greater inﬂammation
was accompanied by adipocyte death, a net decrease in depot size,
and marked deterioration of glucose tolerance and insulin sensitivity.
This enhanced inﬂammatory phenotype is similar to that observed in
animals overexpressing HIF-1α. In aggregate, these ﬁndings suggest a
model where insufﬁcient angiogenesis during high-fat diet leads to
hypoxia, HIF-1α expression, inﬂammation and adipose tissue dysfunc-
tion (Fig. 2). In addition, these studies clearly demonstrate that increased
VEGF-A production and increased vascularization enable adipose tissue
to adapt to rapid expansion caused by acutely increased caloric intake,and protect from the development of insulin resistance and glucose
intolerance.
These results raise the questions: whatmechanisms limit the expres-
sion of VEGF in adipose tissue, and do differences in VEGF production ac-
count for the variation in human adipose tissue expandability and
subsequent protection from inﬂammation and metabolic dysfunction?
Although some studies report decreased levels of VEGF gene expression
in obese humans [23], others report higher levels of expression of
VEGF-A in both subcutaneous and omental fat in obese compared
to lean subjects, and a higher level in omental adipose tissue from
obese insulin-sensitive compared to obese insulin-resistant individuals
[37]. Unpublished results from our own group studying obese female
subjects undergoing bariatric surgery are consistentwith these later ﬁnd-
ings, suggesting that increased VEGF-A levels in adipose tissuemay result
in better vascularization and protection from inﬂammation and insulin
resistance. Moreover, capillary density, as well as the capacity of human
adipose tissue to produce new capillaries ex-vivo, is correlated with
higher VEGF-A levels and increased insulin sensitivity in non-diabetic
obese individuals [38]. Thus, as in mouse models, increased levels of
VEGF-A may facilitate healthy expansion of adipose tissue and protect
from lipotoxicity and metabolic disease.
6. Hypoxia-independent mechanisms of VEGF production
The ﬁnding of beneﬁcial effects of VEGF production and adipose
tissue vascularization, as opposed to the deleterious effects of hypoxia
signaling, suggests that mechanisms that increase VEGF production
independently of hypoxia can confer a protective effect frommetabolic
risk. Several mechanisms can increase VEGF production independently
from classical hypoxia signaling [39,40]. These mechanisms are elicited
in response to changes in cellular energy demands; for example, the
co-activators PGC-1α and PGC-1β induce VEGF expression and angio-
genesis in muscle in response to exercise [41–44]. These co-activators
act on multiple transcription factors, including ERRs, PPARs and NRFs,
to induce a program of adaptation to increased energy demand. The
Fig. 2. Different consequences of HIF expression in tumors and adipose tissue. A. Rapid cell proliferation during tumor growth elicits hypoxia, which activates HIF1 signaling, VEGF
production and angiogenesis. Increased vascularization allows the tumor to grow. B. HIF1 expression in adipose tissue does not elicit VEGF production, but rather to a pro-ﬁbrotic
program, which is followed by inﬂammation, macrophage inﬁltration and cell death.
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complex, and may involve depletion of intracellular oxygen and stabili-
zation of HIF-1α [45], aswell as the direct co-activation of ERRα [43,46].
Through a combination of these and possibly other mechanisms,
PGC-1α and PGC-1β induce VEGF-A production in-vitro, and in-vivo re-
sult in enhancedmuscle vascularization. Similarmechanismsmay oper-
ate in brown adipose tissue, where cold induced capillary expansion is
dependent on VEGF-A production. VEGF-A is induced in a hypoxia-
independent manner [47,48] through activation of PGC-1α in response
to noradrenergic stimulation [47].White adipose tissue contains detect-
able levels of PGC-1α [49,50] and its adipose tissue-speciﬁc ablation re-
sults in insulin resistance [51]. Whether this phenotype is associated
with decreased capillary density and angiogenic potential is an interest-
ing question for future study.
Another metabolism-responsive mechanism reported to increase
VEGF production is the activation of AMP-dependent protein kinase
(AMPK) [52]. AMPK is a central integrator of energy balance, sensing
the ratio of AMP/ATP within cells. AMPK is activated by conditions
that lower cellular ATP, such as nutritional deprivation or hypoxia,
and phosphorylates downstream targets that decrease energy utilization
and enhance ATP production. Pharmacologically, AMPK activity can be
stimulated in the absence of hypoxia by the AMP mimetic AICAR.
AICAR stimulated VEGFmRNA and protein levels in C2C12myotube cul-
tures, and this effect was blocked by a dominant-negative AMPK [53]. In
tumor cells, glucose deprivation caused an increase in VEGF expression,
which was also blocked by expression of dominant-negative AMPK,
and was not accompanied by changes in HIF-1α levels or transcriptional
activity [52]. The mechanism by which AMPK activation results in in-
creased VEGF levels appears to involve stabilization of VEGFmRNA, rath-
er than transcriptional activation of the VEGF gene [52]. More recently,
administration of AICAR increased VEGF mRNA in skeletal muscle of
wild-type mice, but not in mice expressing dominant-negative AMPK
[54]. As AMPK activity is stimulated in adipose tissue of subjects treated
with metformin [55], it would be interesting to determine whether the
insulin-sensitizing actions of this drug are associated with increased
adipose tissue VEGF production.Highly relevant to adipose tissue is the role of the peroxisome
proliferator activated receptors (PPARs) in angiogenesis [56]. In
particular, the role of PPARγ, a master regulator of adipocyte differen-
tiation, is complex. While PPARγ activation inhibits proliferation of
endothelial cells in-vitro [57–59], it has a net pro-angiogenic role in
the context of adipose tissue, as determined by the increased capillary
density and capillary sprouting capacity of adipose tissue obtained
from both mice and humans treated with PPARγ agonist rosiglitazone
[59,60]. In addition, increased levels of VEGF are observed in adipose
tissue of rodents treated with rosiglitazone [59,61]. Furthermore, in-
hibition of PPARγ function in pre-adipocytes prevents not only the
differentiation of adipocytes, but also the formation of vasculature
in-vivo [62]. These results suggest that, while direct activation of endo-
thelial cell PPARγ results in inhibition of angiogenesis, activation of
PPARγ in the context of adipose tissue results in a net pro-angiogenic
effect. This is likely to be due to the secretion of pro-angiogenic factors
from adipocytes in response to PPARγ activation. Indeed, the ability of
mature adipocytes to secrete potent pro-angiogenic factors, including
VEGF, has been recognized for decades [63–67].7. Factors other than VEGF involved in adipose tissue angiogenesis
Numerous pro and anti-angiogenic factors secreted by adipocytes
are likely to control adipose tissue angiogenesis. A recent proteomic
analysis of secreted proteins from adipose tissue depots suggests
that as much as 50% of the adipose tissue secretome is comprised of
proteins that have been implicated in angiogenesis [68], and various
angiogenesis-related factors, shown in Table 1, are reported to be al-
tered in response to obesity and HFD [38,69–73]. One of the barriers
in elucidating the speciﬁc role for these factors in adipose tissue an-
giogenesis is their pleiotropic expression and likely important roles
in multiple tissues, requiring the generation of tissue-speciﬁc models
to deﬁne their speciﬁc roles. Conversely, factors that play important roles
in angiogenesis in other tissues may play minor roles in adipose tissue
[74,75]. Factors that are increased during adipocyte differentiation, are
Table 1
Factors associated with adipose tissue angiogenesis.
Gene/protein Association with adipose tissue angiogenesis References
ANGPTL-4 (Angiopoietin-like 4) Implicated in angiogenesis, lipid metabolism and glucose homeostasis; transcriptionally activated by PPARγ and
hypoxia; highly expressed in adipose tissue, placenta and tumors.
[59,79,85,91,140]
APELIN Highly expressed in adipose tissue; ligand for G-protein coupled receptor APJ; required for vascular development in frog
embryos; pro-angiogenic in human endothelial cells; up-regulated by hypoxia and during pregnancy and lactation.
[35,71,141–143]
PIGF/PLGF (placental growth factor) Interacts with VEGFR1; Inactivation impairs adipose tissue development. [144,145]
HGF (hepatocyte growth factor) Decreased formation of fat pads from 3T3-F442A cells with HGF knockdown. [72]
FGF-1 (ﬁbroblast growth factor-1) Pathological adipose tissue vasculature in FGF-1 knockout mice under HFD. [146]
SPARC/osteonectin/BM40 Enriched in adipose tissue; increased expression in obesity; promotes ﬁbrosis. [147-149]
Leptin Produced exclusively by adipocytes; induced vascularization in angiogenic assays; pro-angiogenic on human um-
bilical vein endothelial cells.
[67,150,151]
Adiponectin Produced exclusively by adipocytes; chemo-attractant for endothelial progenitor cells; pro-angiogenic in human
microvascular and umbilical vein endothelial cells.
[152-154]
Chemerin Ligand for the G protein-coupled receptor CMKLR1; high level expression in mouse and human adipocytes;
pro-angiogenic in human endothelial cells
[155,156]
Ang-2 (angiopoietin-2) Increased in adipose tissue of obese mice; transcriptionally regulated by FOXC2 in adipose tissue. [157,158]
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are thus of heightened relevance in this context.
Angiogenesis-related factors directly regulated in response to
PPARγ activation, include angiopoietin-like 4 (ANGPTL4) [59,76]. This
factor was discovered simultaneously as a fasting-induced adipocyte fac-
tor [77], and as a direct target for PPARγ highly expressed in adipose tis-
sue and placenta [78]. ANGPTL4 inhibits lipoprotein lipase, and its
expression is correlated with alterations in circulating lipids in mouse
models and humans [79–82]. In parallel, ANGPTL4 has been found to be
induced in tumors and normal tissues in response to hypoxia [83–87],
and to have pro-angiogenic effects that affect tissue vascularization and
wound healing [59,88–91]. Overexpression of ANGPTL4 in obese mice
ameliorates insulin resistance and glucose intolerance, even while in-
ducing hyperlipidemia [92]. Whether the protective effect of increased
ANGPTL4 results from increased adipose tissue vascularization or from
inhibition of adipose tissue LPL is not known, but it is interesting to
speculate that ANGPTL4 may be important for stimulating angiogenic
expansion while preventing excess lipid accumulation in rapidly grow-
ing tissues.
In addition to factors secreted from adipocytes, non-adipocyte
cells involved in tissue remodeling could induce adipose tissue angio-
genesis. Inﬁltration of adipose tissue by cells of the immune system
occurs rapidly in response to HFD in mice, and the visceral adipose
depot of insulin-resistant humans is highly inﬂamed [93,94]. While
macrophage inﬁltration may result in inﬂammation-induced insulin
resistance, these cells may also play a beneﬁcial, trophic role, as has
been suggested to occur in other tissues [95]. Indeed, a pro-angiogenic
role for LYVE-1 positive macrophages in epididymal fat pad expansion
has been shown [6], and a role for macrophages in stimulating tumor
angiogenesis is extensively documented [96–100]. The angiogenic role
of tissue macrophages has attributed to factors such as TNFα, IL-8, wnt
and PDGF signaling [101–103], some of which also have important
roles in adipocyte differentiation. Thus, deciphering the relative contri-
bution of factors secreted by adipocytes and immune cells will be impor-
tant for understanding the mechanisms of adipose tissue angiogenesis
under diverse physiological conditions.
8. Developmental mechanisms of adipose tissue angiogenesis
In the paradigm of angiogenic growth described above the critical
pro-angiogenic stimuli emanate from adipose cells undergoing hypoxia
or energetic stress (Fig. 1A). However, an alternative paradigm is one
in which the growth of the vasculature precedes the growth of adipo-
cytes, thus ensuring an adequate blood supply to the expanding tissue
(Fig. 1B). This paradigm functions during adipose tissue development
in the embryo and early post-natal stages, and the possibility exists
that it may also operate in adult tissue. A close association between adi-
pocyte growth and the developing vasculature was noted as far back as1870, where the emergence of adipocytes from well developed vascular
networks led to the suggestion that a robust blood supply was essential
for the development of adipose tissue. Extensivemorphological analyses
of the developing adipose tissue in pig and rodent embryo depots [8]
strongly support the concept that the establishment of a capillary net-
work precedes the emergence of adipocytes during embryonic develop-
ment. Angiogenesis also precedes adipocyte formation during post-natal
growth: In mouse epididymal fat, a dense vascular network in the tip of
the fat pad expands rapidly during post-natal days 0–5, and new adipo-
cytes arise fromwithin the newly formed vessels [6,104]. The activities of
VEGF, VEGFR2, MMPs, and SDF-1 are essential, and administration of
antibodies to VEGF inhibited angiogenesis as well as the emergence of
adipocytes.
A functional requirement for vascular cells in adipocyte differentiation
is also suggested by the experiments of Fukumura et al., mentioned
above, in which implantation of pre adipocytes results in vigorous angio-
genesis and the formation of fat pads [62]. The formation of the capillary
network was dependent on the expression of PPARγ in the implanted
cells, consistentwith amajor role of this transcription factors in regulating
the expression of pro-angiogenic factors, as described above. Strikingly,
inhibition of VEGF signaling blocked not only angiogenic growth but
also the differentiation of the implanted pre-adipocytes, suggesting that
direct interaction with endothelial cells, or other cells associated with
blood vessels, may be crucial for the differentiation of pre-adipocytes
in-vivo. These results are consistentwith recent ﬁndings that the vascula-
ture of adipose tissue is the niche for pre-adipocyte precursors [105,106].
These precursors, labeled using lineage-speciﬁc PPARγ-driven markers,
also express smooth muscle actin, PDGFR-β and NG2, which are charac-
teristic markers of mural cells [105].
Cells within human adipose tissue capillaries formed ex-vivo also
contain adipocyte precursors [107]; interestingly, these cells contained
endothelial cell markers as well as large lipid droplets, glycogen parti-
cles and a displaced nucleus, all features of differentiated adipocytes.
These results suggest that multi-potent cells with capacity for endothe-
lial and/or adipocyte differentiation exist within the vessel wall. This
notion is further supported by the ﬁnding that GFP expression driven
by the Zfp423 promoter can be localized to cells within the adipose
tissue vasculature, including a subset that expresses endothelial cell
markers [108]. Because Zfp423 has been identiﬁed as a factor enriched
in adipocyte precursors, these results are consistent with plasticity in
the endothelial-adipose cell lineage, which has been suggested by others
[109,110].
The ﬁnding that pre-adipocyte precursors reside within the adipose
tissue vasculature, and that inhibition of angiogenic growth inhibits
pre-adipocyte differentiation, suggests that direct, cell–cell interactions
that control angiogenic growth may also be involved in pre-adipocyte
proliferation or differentiation in-vivo (Fig. 3). Experiments in which
adipose stromal cells co-culturedwith endothelial cells display decreased
Fig. 3. Hypothetical model for coordination of angiogenesis and adipocyte prolifera-
tion. A. Quiescent multi-potent progenitors reside within the adipose tissue vasculature.
B. Endothelial cells are stimulated to proliferate by VEGF, resulting in the formation of
tip cells (green) expressing Dll4, which suppresses VEGF signaling in adjacent cells via
activation of Notch, forming new capillary sprouts. This is accompanied by proliferation
of progenitors. C. Progenitors differentiate into adipocytes and/or other cell types such
as endothelial or mural cells.
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with this possibility. In addition to Wnt signaling, Delta (dll4)-Notch
signaling, which is crucial in the formation of new vessels, has also
been associated with adipocyte differentiation [112–114].9. Adipose tissue developmental genes and angiogenesis
Comprehensive analyses of gene expression in human adipose tis-
sue reveal numerous differences related to functions such as lipolysis,
fatty acid synthesis and inﬂammation amongst different depots. These
differences in gene expression are consistent with the different func-
tions of adipose tissue in different regions of the body, and with the
variance in metabolic disease risk associated with expansion of speciﬁc
depots [38]. In efforts to elucidate the developmental origins of these
depots, and the mechanisms by which they attain speciﬁc functions,
the expression of genes related to tissue patterning and embryonic de-
velopment has been studied [115–117]. Importantly, major differences
in expression of genes that determine body patterning have been found
amongst different adipose depots. These include changes in expression
of Hox genes, which are transcription factors that bind DNA through a
60 amino acid helix–turn–helix homeodomain, and control develop-
ment along the anterior–posterior axis. A large proportion of the HOX
gene network is active in adult white adipose tissue [115], and differ-
ences are seen in the levels of expression between whole visceral and
subcutaneous adipose tissues from non-diabetic male humans [118].
In a comprehensive assessment of developmental gene expression
between intra abdominal and subcutaneous depots from mouse and
humans, highly signiﬁcant differences in expression of Hox genes
(HOXA5, HOXC8, HOXC9) were found consistently in both species
[116]. More recently, differences amongst subcutaneous abdominal
and gluteal depots of male and female humans have been reported
[117]. Depot-associated variation included HOXA3, HOXA5, HOXB8,
HOXC8, which were more highly expressed in abdominal adipose
tissue, and HOXA10 and HOXC13, which were highly expressed in
the gluteal depot in both genders. Importantly, variances seen in
whole tissue are also observed when analyzing the stromovascular
fraction, which encompasses a mixed population of endothelial cells,ﬁbroblasts, white blood cells and in all likelihood adipocyte progenitors
[116,117].
The ﬁnding of signiﬁcant differences in developmental gene ex-
pression in the stromovascular fraction of adipose tissue, together
with the possible role for the vasculature as the niche for adipocyte
precursors, raises the question of whether the role of these develop-
mental genes is in fact exerted at the level of vascular development.
Indeed, the vascular system is the ﬁrst organ system developed during
embryogenesis, and growth of tissues and organs is critically dependent
on vascular expansion. Hox genes are important determinants of ante-
rior–posterior development, but act at the cellular level by modulating
functions such as cell adhesion, migration and cell cycle control, and
are important in the process of angiogenic transcriptional regulation
[119].
The developmental genes differentially expressed in adipose tis-
sue depots include several which have been implicated in vascular
patterning and endothelial function. Amongst these is HOXC9, which
is expressed in different vascular beds, is negatively correlated with
growth of human umbilical vein endothelial cells, and impairs vascular
development in zebraﬁsh upon endothelial-speciﬁc overexpression
[119,120]. Another is HOXA9,which is necessary for endothelial cell mi-
gration and tube formation [121], and has been reported to be essential
for inﬂammatory activation of endothelial cells [121–123]. Both HOXC9
and HOXA9 are more highly expressed in subcutaneous compared to
visceral adipose tissue in mice and lean humans, and HOXA9 is more
highly expressed in gluteal compared to abdominal subcutaneous fat
[116]. HOXA5 has also been implicated in vasculature development
[124,125], while correlating with levels of obesity and fat distribution
in humans [117,126]. Distinguishing the relationship between the role
of these genes in vascular development and depot-speciﬁc adipose
tissue growth is an exciting area for future research.
10. Impact of adipose tissue angiogenesis on obesity and insulin
resistance
Several lines of evidence indicate that adipose tissue growth can
be limited by its vascular supply [6–8], and that rapid adipose tissue
expansion, such as that elicited by HFD in mice, is not adequately
paralleled by growth of the capillary network, leading to hypoxia
[20,22,23,35,127]; hypoxic stress in turn can promote inﬂammation
[21] and insulin resistance. Indeed, recent experiments in mouse
models of adipose tissue VEGF over and under expression provide di-
rect and convincing evidence consistent with a critical role for angio-
genesis in determining adipose tissue size, as well as impacting the
metabolic sequelae associated with impaired adipose tissue growth.
As noted above, adipose tissue VEGF-ablated animals display a net
decrease in depot size, accompanied by inﬂammation and marked
deterioration of glucose tolerance and insulin sensitivity, most evident
in response to HFD. Conversely, overexpression of VEGF in adipose
tissue results in increased vascularization, decreased inﬂammation,
and amelioration of HFD-induced insulin resistance [33–35].
Several other instances have been described in which pro- and
anti-angiogenic factors impact obesity and/or insulin resistance. For
example, overexpression of ANGPTL4 in obese mice ameliorates
insulin resistance and glucose intolerance, even while inducing hyper-
lipidemia [92]. In another example, mice lacking 11β-hydroxysteroid
dehydrogenase type 1, which are resistant to HFD-induced metabolic
disease even while displaying adipose tissue expansion, have higher
adipose tissue vascular density, increased levels of pro-angiogenic fac-
tormRNA levels, and increased secretion of pro-angiogenic factors [35].
While human studies are mostly correlations, existing data indicate
that expansion of adipose tissue in adults is accompanied by induction
of a pro-angiogenic gene expression proﬁle [70]. Moreover, capillary
density, as well as the capacity of human adipose tissue to produce
new capillaries ex-vivo, is correlated with higher VEGF-A levels and
increased insulin sensitivity in non-diabetic obese individuals [37,38].
469S. Corvera, O. Gealekman / Biochimica et Biophysica Acta 1842 (2014) 463–472Thus, as inmice, increased VEGF-A levels in adipose tissuemay result in
better vascularization and protection from inﬂammation and insulin
resistance.
11. Is adipose tissue angiogenesis a therapeutic target in Type-2
diabetes?
Initial recognition of a clear association between obesity and insulin
resistance suggested that limiting the accretion of fat might also limit
the risk ofmetabolic disease. Knowledge about the absolute requirement
for angiogenesis in adipose tissue expansion led to early experiments in
which anti-angiogenic compounds were used as possible anti-obesity
and anti-diabetes therapeutic approaches [128,129]. These approaches
demonstrated decreased fat accumulation; however, their simultaneous
effects to decrease food consumption confounded the interpretation of
the beneﬁcial results of anti-angiogenic therapy.
Subsequent demonstration that insulin resistance and disease risk
most likely stem from insufﬁcient fat storage and ensuing lipotoxicity
and inﬂammation, rather than directly from increased fat accumulation
[69,130–132], logically has limited enthusiasm for approaches that focus
on deceasing adipose tissue expansion without decreasing caloric input
or enhancing energetic output. Indeed, the enhanced risk of diabetes
accompanying lipodystrophy [133–135] and, conversely, the improved
metabolic state in several models of increased adiposity [136,137], fur-
ther suggest that impairing adipose tissue growth is not a promising
approach for ameliorating metabolic disease.
While anti-angiogenesis approaches in which appropriate adipose
tissue vascularization and growth are compromised are unlikely to be
of therapeutic beneﬁt, the adipose tissue vasculature remains a prom-
ising site for identiﬁcation of new therapeutic targets. Accumulating
evidence for the adipose tissue vasculature as the niche for adipocyte
progenitors raises the possibility of vasculature-targeted approaches
to enhance the generation of healthy adipocytes, mitigating adipocyte
stress and inﬂammation. Moreover, the vasculature is likely to be the
niche for precursor cells giving rise to brite/beige adipocytes, which are
metabolically active andmay decreasemetabolic disease risk [138,139].
Better understanding of the mechanisms that induce adipose tissue
angiogenesis, and of the role of the vasculature in adipose tissue func-
tion, will in all likelihood provide new and perhaps unexpected insights
into ways adipose tissue biology can be targeted to improve human
health.
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